Compare McCormick & Company, Incorporated (MKC) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Nuwellis Inc — how do they compare? McCormick & Company, Incorporated trades at $45.62 (market cap $12.20B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: McCormick & Company, Incorporated is far larger — about 5545.5× Nuwellis Inc's market cap, and McCormick & Company, Incorporated pays a 4.24% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Nuwellis Inc for 26 Days on average.
| MKC | NUWE | |
|---|---|---|
Market Cap | $12.20B | $2.20M |
Volume | 4,117,008 | 121,544 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $146.65 |
52-Week Low | $44.14 | $0.68 |
Typical Hold Time | 67 Days | 26 Days |
Enterprise Value | $16.88B | -$1.52M |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $45.94, up 1.19% today, with a bearish technical signal but strong fundamentals. Recent Q3 2026 earnings beat estimates with $0.86 EPS, driven by 17% sales growth and margin expansion. The stock appears undervalued with a P/E of 8.18 and offers a dividend yield. Cash flow trends show operational strength despite a net outflow in 2025.
The outlook is mixed: solid earnings growth and a $53.50 consensus price target suggest upside, but technical weakness and competitive pressures pose risks. Investor sentiment is cautious with a 'Hold' analyst consensus. Key catalysts include continued margin improvement and integration of recent acquisitions.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
